| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniela Regazzo, Mattia Barbot, Carla Scaroni, Nora Albiger, Gianluca Occh. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Reviews in endocrine & metabolic disorders. vol 21. issue 1. 2021-02-16. PMID:31933128. |
gip has a variety of effects on different systems, including the potentiation of insulin secretion from pancreatic β-cells after food intake (i.e. |
2021-02-16 |
2023-08-13 |
human |
| Okechi S Oduori, Naoya Murao, Kenju Shimomura, Harumi Takahashi, Quan Zhang, Haiqiang Dou, Shihomi Sakai, Kohtaro Minami, Belen Chanclon, Claudia Guida, Lakshmi Kothegala, Johan Tolö, Yuko Maejima, Norihide Yokoi, Yasuhiro Minami, Takashi Miki, Patrik Rorsman, Susumu Sein. Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes. The Journal of clinical investigation. vol 130. issue 12. 2021-02-16. PMID:33196462. |
normally, the incretins glp-1 and glucose-dependent insulinotropic polypeptide (gip) jointly maintain normal blood glucose levels by stimulation of insulin secretion in pancreatic β cells. |
2021-02-16 |
2023-08-13 |
mouse |
| Bo Ahrén, Yuchiro Yamada, Yutaka Sein. Islet adaptation in GIP receptor knockout mice. Peptides. vol 125. 2021-02-08. PMID:31522751. |
in this study, we examined the insulin response to intravenous glucose by measuring glucose, insulin and c-peptide after intravenous glucose (0.35 g/kg) in 5-h fasted female gip receptor ko mice and their wild-type (wt) littermates. |
2021-02-08 |
2023-08-13 |
mouse |
| Bo Ahrén, Yuchiro Yamada, Yutaka Sein. Islet adaptation in GIP receptor knockout mice. Peptides. vol 125. 2021-02-08. PMID:31522751. |
the 1 min insulin and c-peptide responses to intravenous glucose were significantly enhanced in gip receptor ko mice (n = 26) compared to wt mice (n = 30) as was beta cell function (area under the 50 min c-peptide curve divided by area under the 50 min curve for glucose) (p = 0.001). |
2021-02-08 |
2023-08-13 |
mouse |
| Bo Ahrén, Yuchiro Yamada, Yutaka Sein. Islet adaptation in GIP receptor knockout mice. Peptides. vol 125. 2021-02-08. PMID:31522751. |
we conclude that there is a beta cell adaptation in gip receptor ko mice resulting in enhanced insulin secretion after intravenous glucose to which slight long-term reduction in circulating glucose in these mice may contribute. |
2021-02-08 |
2023-08-13 |
mouse |
| Mikkel B Christensen, Lærke S Gasbjerg, Sebastian M Heimbürger, Signe Stensen, Tina Vilsbøll, Filip K Kno. GIP's involvement in the pathophysiology of type 2 diabetes. Peptides. vol 125. 2021-02-08. PMID:31682875. |
this overview outlines and discusses the impaired insulin responses to gip as well as the effect of gip on glucagon secretion and the potential involvement of gip in the obesity and bone disease associated with type 2 diabetes. |
2021-02-08 |
2023-08-13 |
Not clear |
| Lærke S Gasbjerg, Natasha C Bergmann, Signe Stensen, Mikkel B Christensen, Mette M Rosenkilde, Jens J Holst, Michael Nauck, Filip K Kno. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. vol 125. 2021-02-08. PMID:31693916. |
glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) potentiate glucose-induced insulin secretion and are therefore thought to be responsible for the incretin effect. |
2021-02-08 |
2023-08-13 |
Not clear |
| Signe Stensen, Lærke Smidt Gasbjerg, Mads Marstrand Helsted, Bolette Hartmann, Mikkel Bring Christensen, Filip Krag Kno. GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications. Peptides. vol 125. 2021-02-08. PMID:31715213. |
glucose-dependent insulinotropic polypeptide (gip) is secreted from the gut and potentiates insulin secretion in a glucose-dependent manner. |
2021-02-08 |
2023-08-13 |
human |
| Nigel Irwin, Victor A Gault, Finbarr P M O'Harte, Peter R Flat. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides. vol 125. 2021-02-08. PMID:31733230. |
blockade of gastric inhibitory polypeptide (gip) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. |
2021-02-08 |
2023-08-13 |
Not clear |
| Nigel Irwin, Victor A Gault, Finbarr P M O'Harte, Peter R Flat. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides. vol 125. 2021-02-08. PMID:31733230. |
despite a recognised physiological role for gip as an insulin secretagogue to control postprandial blood glucose levels, growing evidence reveals important actions of gip on adipocytes and promotion of fat deposition in tissues. |
2021-02-08 |
2023-08-13 |
Not clear |
| Nigel Irwin, Victor A Gault, Finbarr P M O'Harte, Peter R Flat. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides. vol 125. 2021-02-08. PMID:31733230. |
as such, blockade of gip receptor (gipr) action has been proposed as a means to counter insulin resistance, and improve metabolic status in obesity and related diabetes. |
2021-02-08 |
2023-08-13 |
Not clear |
| Nigel Irwin, Victor A Gault, Finbarr P M O'Harte, Peter R Flat. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides. vol 125. 2021-02-08. PMID:31733230. |
sustained administration of peptide-based gipr inhibitors, low molecular weight gipr antagonists, gipr neutralising antibodies as well as genetic knockout of gipr's or vaccination against gip all demonstrate amelioration of insulin resistance and reduced body weight gain in response to high fat feeding. |
2021-02-08 |
2023-08-13 |
Not clear |
| Rabeet Khan, Alejandra Tomas, Guy A Rutte. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. Peptides. vol 125. 2021-02-08. PMID:31751656. |
glucose-dependent insulinotropic polypeptide (gip) is a gut-derived incretin that, in common with glucagon-like peptide-1 (glp-1), has both insulin releasing and extra-pancreatic glucoregulatory actions. |
2021-02-08 |
2023-08-13 |
Not clear |
| Rabeet Khan, Alejandra Tomas, Guy A Rutte. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. Peptides. vol 125. 2021-02-08. PMID:31751656. |
gip is released in response to glucose or fat absorption and acts on the gip receptor (gipr) to potentiate insulin release from pancreatic beta cells. |
2021-02-08 |
2023-08-13 |
Not clear |
| Rabeet Khan, Alejandra Tomas, Guy A Rutte. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. Peptides. vol 125. 2021-02-08. PMID:31751656. |
there is now evidence to suggest that low levels of gip are secreted from alpha cells and may act in a paracrine manner to prime neighboring beta cells for insulin release. |
2021-02-08 |
2023-08-13 |
Not clear |
| Frank Reimann, Eleftheria Diakogiannaki, Catherine E Moss, Fiona M Gribbl. Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. Peptides. vol 125. 2021-02-08. PMID:31756367. |
glucose-dependent insulinotropic polypeptide (gip) is a gut hormone secreted from the upper small intestine, which plays an important physiological role in the control of glucose metabolism through its incretin action to enhance glucose-dependent insulin secretion. |
2021-02-08 |
2023-08-13 |
Not clear |
| Sravan K Thondam, Daniel J Cuthbertson, John P H Wildin. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides. vol 125. 2021-02-08. PMID:31759125. |
antagonising gip actions through genetic and chemical disruption in mice models prevented diet induced obesity and improved insulin sensitivity. |
2021-02-08 |
2023-08-13 |
mouse |
| Amanda A Greenwell, Jadin J Chahade, John R Usshe. Cardiovascular biology of the GIP receptor. Peptides. vol 125. 2021-02-08. PMID:31812593. |
glucose-dependent insulinotropic polypeptide (gip) is a gut hormone secreted primarily from enteroendocrine k cells in the duodenum and proximal jejunum following nutrient ingestion, primarily acting on islet β-cells to potentiate insulin secretion in a glucose-dependent manner. |
2021-02-08 |
2023-08-13 |
Not clear |
| Jens Juul Holst, Mette Marie Rosenkild. Recent advances of GIP and future horizons. Peptides. vol 125. 2021-02-08. PMID:31838219. |
conventionally, gip is thought of as an important incretin hormone regulating postprandial insulin secretion in glucose tolerant individuals, but such effects are weak or absent in patients with type 2 diabetes, and gip has been proposed to an obesity-promoting hormone, rather than the opposite. |
2021-02-08 |
2023-08-13 |
human |
| Farnaz Keyhani-Nejad, Renate Luisa Barbosa Yanez, Margrit Kemper, Rita Schueler, Olga Pivovarova-Ramich, Natalia Rudovich, Andreas F H Pfeiffe. Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction. Peptides. vol 125. 2021-02-08. PMID:31870938. |
endogenously released gip reduces and glp-1 increases hepatic insulin extraction. |
2021-02-08 |
2023-08-13 |
mouse |